PASTIC Dspace Repository

Effects of superdisintegrants in oral dissolving formulation of cinitapride tablets

Show simple item record

dc.contributor.author Atta-Ur-Rehman
dc.contributor.author Rabia Bushra
dc.contributor.author Anwar Ejaz Beg
dc.contributor.author Huma Ali
dc.contributor.author Farya Zafar
dc.contributor.author Maria Ashfaq
dc.contributor.author Shazia Alam
dc.contributor.author Omer Mustapha
dc.contributor.author Shumaila Shafique
dc.date.accessioned 2023-01-20T06:52:36Z
dc.date.available 2023-01-20T06:52:36Z
dc.date.issued 2018-03-07
dc.identifier.citation Bushra, R., Beg, A. E., Ali, H., Zafar, F., Ashfaq, M., Alam, S., ... & Shafique, S. (2018). Effects of superdisintegrants in oral dissolving formulation of cinitapride tablets. Pakistan Journal of Pharmaceutical Sciences, 31. en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/16299
dc.description.abstract The initiation of newer techniques and development of mouth dissolving (MD) products has created new avenues of higher patients’ compliance. MD formulations are actually lessen the difficulties associated with solid swallowing with better bioavailability of especially poorly soluble drugs. In the current study mouth dissolving tablet (MDT) formulations of cinitapride (1 mg) were prepared by direct compression method using various proportion and combination of superdisintegrants. Nine formulations in three batches were compressed by incorporating low (2%), intermediate (6%) and higher (10%) levels of crospovidone, croscarmellose sodium, sodium starch glycolate. Micromeritic assessment of the powder blends were carried out and were found within the acceptable official limits. All newly developed trial formulations were exposed to different pharmacopoeial and non-pharmacopoeial testing. It was found that FC2 trial tablets containing polyplasdone XL® (crospovidone) at level of 6% (4.5 mg) presented the best physico-chemical attributes deemed to be desirable for the ODT products. Disintegration and wetting time of optimized FC2 was computed between 15-17 and 12-15 seconds respectively. The assay and content uniformity of FC2 were estimated to be 100.02±0.36 and 99.66±1.70 percent correspondingly. On the basis of the findings it was concluded that MDT could be successfully developed by incorporating appropriate concentration of superdisintegrant and their combinations. en_US
dc.language.iso en en_US
dc.publisher Karachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachi en_US
dc.subject Mouth dissolving tablets en_US
dc.subject cinitapride en_US
dc.subject micromeritic assessments en_US
dc.subject formulation characterization en_US
dc.title Effects of superdisintegrants in oral dissolving formulation of cinitapride tablets en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account